Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC has demonstrated a promising financial outlook, highlighted by a 95% probability of success for its psilocybin therapy, COMP360, following positive data from the COMP005 trial. The therapy has shown a statistically significant -3.6 point reduction on the MADRS scale, indicating its effectiveness in treating treatment-resistant depression. Additionally, the anticipated low-frequency dosing of COMP360, requiring only 2–4 sessions per year, positions it favorably against existing therapies, potentially increasing patient adherence and enhancing market adoption.

Bears say

Compass Pathways PLC is facing a negative outlook due to increased research and development expenses associated with advancing its COMP360 Phase 3 clinical trials, which exceeded prior estimates and impacted cash reserves, totaling $221.9 million as of June 30. Additionally, competitive pressures could arise if peers in the mental health space generate compelling data, potentially putting further downward pressure on Compass's stock. The company's strategic reorganization has led to decreased general and administrative expenses; however, reliance on a narrow cash position amidst rising costs and market competition raises substantial concerns regarding the company's financial stability and growth prospects.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.